First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

Abstract Background The regimen of nivolumab plus ipilimumab (NI) has been recommended by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Malignant Pleural Mesothelioma (Version 1.2022) and Chinese Guidelines for the Clinical Diagnosis and Treatment of Malignant Pl...

Full description

Bibliographic Details
Main Authors: Liu Yang, Xiaobing Song, Wanxian Zeng, Zhiwei Zheng, Wenqiang Lin
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Cost-effectiveness
Malignant pleural mesothelioma
Nivolumab
Ipilimumab
First-line treatment
Online Access:https://doi.org/10.1186/s13023-023-02925-w

Internet

https://doi.org/10.1186/s13023-023-02925-w

Similar Items